BCR and ovarian cancer: As demonstrated in Figures 1E, F, the TCR and BCR repertoires in patients with malignant ovarian tumors exhibited significantly greater heterogeneity compared to those in patients with benign ovarian tumors (TCR: p = 0.0022; BCR: p = 0.02; Wilcoxon tests).